Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

Kausik K. Ray, Robert M. Stoekenbroek, David Kallend, Toshiyuki Nishikido, Lawrence A. Leiter, Ulf Landmesser, R. Scott Wright, Peter L.J. Wijngaard, John J.P. Kastelein

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Importance: Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies that require frequent dosing are reliant on patient adherence, and poor adherence is associated with worse clinical outcomes. Objective: To determine whether inclisiran, a small interfering RNA, reduces mean LDL-C exposure with an infrequent dosing regimen. Design, Setting, and Participants: Prespecified analysis of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial. Participants were followed up monthly for LDL-C levels and proprotein convertase subtilisin-kexin type 9 (PCSK9) measurements as well as safety until their LDL-C levels had returned to within 20% of their change from baseline (maximum 360 days). The study included patients with elevated LDL-C despite maximally tolerated statin therapy. Data were analyzed between January 11, 2016, and June 7, 2017. Interventions: One dose (200, 300, or 500 mg on day 1) or 2 doses (100, 200, or 300 mg on days 1 and 90) of inclisiran sodium or placebo. Main Outcomes and Measures: Duration of time to return to within 20% of change from baseline for LDL-C levels and time-averaged LDL-C reductions over 1 year. Results: At baseline, among the 501 participants, 65% were men (n = 326 of 501), mean age was 63 years, 6% had familial hypercholesterolemia (n = 28 of 501), and 69% had established ASCVD (n = 347 of 501). Baseline LDL-C was 128 mg/dL among 501 randomized participants. The percentage of participants who were followed up to day 360 because their LDL-C levels had not returned to within 20% of their change from baseline ranged from 48.3% to 65.0% for those receiving a single dose and between 55.9% and 83.1% of those receiving 2 doses, with similar effects observed for PCSK9. Time-averaged reduction in LDL-C levels over 1 year after a single dose ranged from 29.5% to 38.7% (P <.001 between groups) and from 29.9% to 46.4% (P <.001 between groups) for those who received 2 doses. The 2-dose 300-mg regimen produced the highest proportion of responders at day 360 and the greatest mean reduction in LDL-C over 1 year. Incidence of adverse events was similar through to 1 year. Conclusions and Relevance: Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year. Inclisiran may offer a novel approach to LDL-C reduction with the convenience of infrequent dosing.

Original languageEnglish (US)
JournalJAMA cardiology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

LDL Cholesterol
Randomized Controlled Trials
Placebos
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipoproteinemia Type II
Patient Compliance
Small Interfering RNA
Therapeutics
Sodium
Outcome Assessment (Health Care)
Clinical Trials
Lipids
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., ... Kastelein, J. J. P. (Accepted/In press). Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA cardiology. https://doi.org/10.1001/jamacardio.2019.3502

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels : One-Year Follow-up of the ORION-1 Randomized Clinical Trial. / Ray, Kausik K.; Stoekenbroek, Robert M.; Kallend, David; Nishikido, Toshiyuki; Leiter, Lawrence A.; Landmesser, Ulf; Wright, R. Scott; Wijngaard, Peter L.J.; Kastelein, John J.P.

In: JAMA cardiology, 01.01.2019.

Research output: Contribution to journalArticle

Ray, Kausik K. ; Stoekenbroek, Robert M. ; Kallend, David ; Nishikido, Toshiyuki ; Leiter, Lawrence A. ; Landmesser, Ulf ; Wright, R. Scott ; Wijngaard, Peter L.J. ; Kastelein, John J.P. / Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels : One-Year Follow-up of the ORION-1 Randomized Clinical Trial. In: JAMA cardiology. 2019.
@article{59e7bbd1f92b4bceb8322b90ebd4e237,
title = "Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial",
abstract = "Importance: Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies that require frequent dosing are reliant on patient adherence, and poor adherence is associated with worse clinical outcomes. Objective: To determine whether inclisiran, a small interfering RNA, reduces mean LDL-C exposure with an infrequent dosing regimen. Design, Setting, and Participants: Prespecified analysis of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial. Participants were followed up monthly for LDL-C levels and proprotein convertase subtilisin-kexin type 9 (PCSK9) measurements as well as safety until their LDL-C levels had returned to within 20{\%} of their change from baseline (maximum 360 days). The study included patients with elevated LDL-C despite maximally tolerated statin therapy. Data were analyzed between January 11, 2016, and June 7, 2017. Interventions: One dose (200, 300, or 500 mg on day 1) or 2 doses (100, 200, or 300 mg on days 1 and 90) of inclisiran sodium or placebo. Main Outcomes and Measures: Duration of time to return to within 20{\%} of change from baseline for LDL-C levels and time-averaged LDL-C reductions over 1 year. Results: At baseline, among the 501 participants, 65{\%} were men (n = 326 of 501), mean age was 63 years, 6{\%} had familial hypercholesterolemia (n = 28 of 501), and 69{\%} had established ASCVD (n = 347 of 501). Baseline LDL-C was 128 mg/dL among 501 randomized participants. The percentage of participants who were followed up to day 360 because their LDL-C levels had not returned to within 20{\%} of their change from baseline ranged from 48.3{\%} to 65.0{\%} for those receiving a single dose and between 55.9{\%} and 83.1{\%} of those receiving 2 doses, with similar effects observed for PCSK9. Time-averaged reduction in LDL-C levels over 1 year after a single dose ranged from 29.5{\%} to 38.7{\%} (P <.001 between groups) and from 29.9{\%} to 46.4{\%} (P <.001 between groups) for those who received 2 doses. The 2-dose 300-mg regimen produced the highest proportion of responders at day 360 and the greatest mean reduction in LDL-C over 1 year. Incidence of adverse events was similar through to 1 year. Conclusions and Relevance: Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year. Inclisiran may offer a novel approach to LDL-C reduction with the convenience of infrequent dosing.",
author = "Ray, {Kausik K.} and Stoekenbroek, {Robert M.} and David Kallend and Toshiyuki Nishikido and Leiter, {Lawrence A.} and Ulf Landmesser and Wright, {R. Scott} and Wijngaard, {Peter L.J.} and Kastelein, {John J.P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamacardio.2019.3502",
language = "English (US)",
journal = "JAMA Cardiology",
issn = "2380-6583",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels

T2 - One-Year Follow-up of the ORION-1 Randomized Clinical Trial

AU - Ray, Kausik K.

AU - Stoekenbroek, Robert M.

AU - Kallend, David

AU - Nishikido, Toshiyuki

AU - Leiter, Lawrence A.

AU - Landmesser, Ulf

AU - Wright, R. Scott

AU - Wijngaard, Peter L.J.

AU - Kastelein, John J.P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Importance: Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies that require frequent dosing are reliant on patient adherence, and poor adherence is associated with worse clinical outcomes. Objective: To determine whether inclisiran, a small interfering RNA, reduces mean LDL-C exposure with an infrequent dosing regimen. Design, Setting, and Participants: Prespecified analysis of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial. Participants were followed up monthly for LDL-C levels and proprotein convertase subtilisin-kexin type 9 (PCSK9) measurements as well as safety until their LDL-C levels had returned to within 20% of their change from baseline (maximum 360 days). The study included patients with elevated LDL-C despite maximally tolerated statin therapy. Data were analyzed between January 11, 2016, and June 7, 2017. Interventions: One dose (200, 300, or 500 mg on day 1) or 2 doses (100, 200, or 300 mg on days 1 and 90) of inclisiran sodium or placebo. Main Outcomes and Measures: Duration of time to return to within 20% of change from baseline for LDL-C levels and time-averaged LDL-C reductions over 1 year. Results: At baseline, among the 501 participants, 65% were men (n = 326 of 501), mean age was 63 years, 6% had familial hypercholesterolemia (n = 28 of 501), and 69% had established ASCVD (n = 347 of 501). Baseline LDL-C was 128 mg/dL among 501 randomized participants. The percentage of participants who were followed up to day 360 because their LDL-C levels had not returned to within 20% of their change from baseline ranged from 48.3% to 65.0% for those receiving a single dose and between 55.9% and 83.1% of those receiving 2 doses, with similar effects observed for PCSK9. Time-averaged reduction in LDL-C levels over 1 year after a single dose ranged from 29.5% to 38.7% (P <.001 between groups) and from 29.9% to 46.4% (P <.001 between groups) for those who received 2 doses. The 2-dose 300-mg regimen produced the highest proportion of responders at day 360 and the greatest mean reduction in LDL-C over 1 year. Incidence of adverse events was similar through to 1 year. Conclusions and Relevance: Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year. Inclisiran may offer a novel approach to LDL-C reduction with the convenience of infrequent dosing.

AB - Importance: Sustained reductions in low-density lipoprotein cholesterol (LDL-C) with lipid-lowering therapies that require frequent dosing are reliant on patient adherence, and poor adherence is associated with worse clinical outcomes. Objective: To determine whether inclisiran, a small interfering RNA, reduces mean LDL-C exposure with an infrequent dosing regimen. Design, Setting, and Participants: Prespecified analysis of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial. Participants were followed up monthly for LDL-C levels and proprotein convertase subtilisin-kexin type 9 (PCSK9) measurements as well as safety until their LDL-C levels had returned to within 20% of their change from baseline (maximum 360 days). The study included patients with elevated LDL-C despite maximally tolerated statin therapy. Data were analyzed between January 11, 2016, and June 7, 2017. Interventions: One dose (200, 300, or 500 mg on day 1) or 2 doses (100, 200, or 300 mg on days 1 and 90) of inclisiran sodium or placebo. Main Outcomes and Measures: Duration of time to return to within 20% of change from baseline for LDL-C levels and time-averaged LDL-C reductions over 1 year. Results: At baseline, among the 501 participants, 65% were men (n = 326 of 501), mean age was 63 years, 6% had familial hypercholesterolemia (n = 28 of 501), and 69% had established ASCVD (n = 347 of 501). Baseline LDL-C was 128 mg/dL among 501 randomized participants. The percentage of participants who were followed up to day 360 because their LDL-C levels had not returned to within 20% of their change from baseline ranged from 48.3% to 65.0% for those receiving a single dose and between 55.9% and 83.1% of those receiving 2 doses, with similar effects observed for PCSK9. Time-averaged reduction in LDL-C levels over 1 year after a single dose ranged from 29.5% to 38.7% (P <.001 between groups) and from 29.9% to 46.4% (P <.001 between groups) for those who received 2 doses. The 2-dose 300-mg regimen produced the highest proportion of responders at day 360 and the greatest mean reduction in LDL-C over 1 year. Incidence of adverse events was similar through to 1 year. Conclusions and Relevance: Treatment with inclisiran resulted in durable reductions in LDL-C over 1 year. Inclisiran may offer a novel approach to LDL-C reduction with the convenience of infrequent dosing.

UR - http://www.scopus.com/inward/record.url?scp=85072756121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072756121&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2019.3502

DO - 10.1001/jamacardio.2019.3502

M3 - Article

C2 - 31553410

AN - SCOPUS:85072756121

JO - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

ER -